AU2001273661A1 - Methods of screening for alzheimer's disease - Google Patents
Methods of screening for alzheimer's diseaseInfo
- Publication number
- AU2001273661A1 AU2001273661A1 AU2001273661A AU7366101A AU2001273661A1 AU 2001273661 A1 AU2001273661 A1 AU 2001273661A1 AU 2001273661 A AU2001273661 A AU 2001273661A AU 7366101 A AU7366101 A AU 7366101A AU 2001273661 A1 AU2001273661 A1 AU 2001273661A1
- Authority
- AU
- Australia
- Prior art keywords
- alzheimer
- screening
- disease
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/40—Population genetics; Linkage disequilibrium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Hematology (AREA)
- Evolutionary Biology (AREA)
- Theoretical Computer Science (AREA)
- Pathology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Medical Informatics (AREA)
- Ecology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Physiology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21515100P | 2000-06-30 | 2000-06-30 | |
US60215151 | 2000-06-30 | ||
PCT/US2001/041224 WO2002002000A2 (en) | 2000-06-30 | 2001-06-29 | Methods of screening for alzheimer's disease |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001273661A1 true AU2001273661A1 (en) | 2002-01-14 |
Family
ID=22801869
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001273661A Abandoned AU2001273661A1 (en) | 2000-06-30 | 2001-06-29 | Methods of screening for alzheimer's disease |
Country Status (3)
Country | Link |
---|---|
US (1) | US20040053251A1 (en) |
AU (1) | AU2001273661A1 (en) |
WO (1) | WO2002002000A2 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040248092A1 (en) * | 2000-05-26 | 2004-12-09 | Vance Jeffrey M | Methods of screening for parkinsons's disease |
US20040014109A1 (en) * | 2002-05-23 | 2004-01-22 | Pericak-Vance Margaret A. | Methods and genes associated with screening assays for age at onset and common neurodegenerative diseases |
AU2003251962A1 (en) * | 2002-07-08 | 2004-01-23 | Duke University | Screening for alzheimer's disease |
US20060246437A1 (en) * | 2003-07-11 | 2006-11-02 | Pericak-Vance Margaret A | Genetic susceptibility genes for asthma and atopy and asthma-related and atopic-related phenotypes |
US20050191652A1 (en) * | 2003-11-03 | 2005-09-01 | Vance Jeffery M. | Identification of genetic forms of a gene that leads to high risk for parkinson disease |
US20060068428A1 (en) * | 2003-11-03 | 2006-03-30 | Duke University | Identification of genetic markers associated with parkinson disease |
US7790390B2 (en) | 2004-10-27 | 2010-09-07 | Duke University | Methods for identifying an individual at increased risk of developing coronary artery disease |
US7807465B2 (en) | 2004-10-27 | 2010-10-05 | Duke University | Methods for identifying an individual at increased risk of developing coronary artery disease |
US20060200878A1 (en) | 2004-12-21 | 2006-09-07 | Linda Lutfiyya | Recombinant DNA constructs and methods for controlling gene expression |
US7771937B2 (en) * | 2005-05-20 | 2010-08-10 | University Of Washington | Methods for predicting late onset Alzheimer disease in an individual |
US20070148661A1 (en) * | 2005-07-19 | 2007-06-28 | Duke University | LSAMP Gene Associated With Cardiovascular Disease |
US20090226420A1 (en) * | 2005-11-10 | 2009-09-10 | Elizabeth Hauser | Methods of Determining the Risk of Developing Coronary Artery Disease |
CN103169949A (en) * | 2005-11-16 | 2013-06-26 | 潘塔希生物科学股份有限公司 | Pharmaceutical composition for treating or preventing ovarian cancer |
CN101516401A (en) * | 2006-08-21 | 2009-08-26 | 诺瓦提斯公司 | Biomarkers for Alzheimer's disease progression |
EP2522753B1 (en) * | 2007-08-13 | 2014-04-02 | Baxter International Inc. | IVIG modulation of chemokines for treatment of Multiple Sclerosis, Alzheimer's disease, and Parkinson's disease |
US10395759B2 (en) | 2015-05-18 | 2019-08-27 | Regeneron Pharmaceuticals, Inc. | Methods and systems for copy number variant detection |
JP6765433B2 (en) | 2016-02-12 | 2020-10-07 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Methods for detecting anomalous karyotypes |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5374525A (en) * | 1992-09-30 | 1994-12-20 | University Of Utah Research Foundation | Methods to determine predisposition to hypertension and association of variant angiotensinogen gene and hypertension |
DE69333461T2 (en) * | 1992-10-13 | 2005-03-24 | Duke University | METHOD FOR DETECTING Alzheimer's disease |
US5449604A (en) * | 1992-10-21 | 1995-09-12 | University Of Washington | Chromosome 14 and familial Alzheimers disease genetic markers and assays |
US5879884A (en) * | 1994-12-29 | 1999-03-09 | Peroutka; Stephen J. | Diagnosis of depression by linkage of a polymorphic marker to a segment of chromosome 19P13 bordered by D19S247 and D19S394 |
US5986054A (en) * | 1995-04-28 | 1999-11-16 | The Hospital For Sick Children, Hsc Research And Development Limited Partnership | Genetic sequences and proteins related to alzheimer's disease |
US5958684A (en) * | 1995-10-02 | 1999-09-28 | Van Leeuwen; Frederik Willem | Diagnosis of neurodegenerative disease |
US6108635A (en) * | 1996-05-22 | 2000-08-22 | Interleukin Genetics, Inc. | Integrated disease information system |
US5922556A (en) * | 1997-07-03 | 1999-07-13 | The Trustees Of Columbia University In The City Of New York | Parkinson's disease tests |
US6342350B1 (en) * | 1997-09-05 | 2002-01-29 | The General Hospital Corporation | Alpha-2-macroglobulin diagnostic test |
US20020037508A1 (en) * | 2000-01-19 | 2002-03-28 | Michele Cargill | Human single nucleotide polymorphisms |
US20040248092A1 (en) * | 2000-05-26 | 2004-12-09 | Vance Jeffrey M | Methods of screening for parkinsons's disease |
US20040014109A1 (en) * | 2002-05-23 | 2004-01-22 | Pericak-Vance Margaret A. | Methods and genes associated with screening assays for age at onset and common neurodegenerative diseases |
US20060068428A1 (en) * | 2003-11-03 | 2006-03-30 | Duke University | Identification of genetic markers associated with parkinson disease |
US20050191652A1 (en) * | 2003-11-03 | 2005-09-01 | Vance Jeffery M. | Identification of genetic forms of a gene that leads to high risk for parkinson disease |
US7807465B2 (en) * | 2004-10-27 | 2010-10-05 | Duke University | Methods for identifying an individual at increased risk of developing coronary artery disease |
-
2001
- 2001-06-29 AU AU2001273661A patent/AU2001273661A1/en not_active Abandoned
- 2001-06-29 US US10/311,668 patent/US20040053251A1/en not_active Abandoned
- 2001-06-29 WO PCT/US2001/041224 patent/WO2002002000A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2002002000A2 (en) | 2002-01-10 |
US20040053251A1 (en) | 2004-03-18 |
WO2002002000A3 (en) | 2002-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001233299A1 (en) | Methods for treating alzheimer's disease | |
AU2002219824A1 (en) | Compositions and methods for diagnosing alzheimer's disease | |
AU2001273132A1 (en) | Compounds to treat alzheimer's disease | |
AU7708498A (en) | Nematode model for alzheimer's disease | |
AU2610901A (en) | Predictive diagnostic for alzheimer's disease | |
AU2865000A (en) | Alpha-2-macroglobulin therapies and drug screening methods for alzheimer's disease | |
AU2001273661A1 (en) | Methods of screening for alzheimer's disease | |
AU2001264950A1 (en) | Methods of screening for parkinson's disease | |
AU2001236592A1 (en) | Methods for diagnosis of alzheimer's disease | |
AU2002315131A1 (en) | Aminediols as agents for the treatment of alzheimer's disease | |
AU2001281034A1 (en) | Alzheimer's tester | |
AU2002246490A1 (en) | Method of treating parkinson's disease | |
AUPR202400A0 (en) | Method of screening for inhibitors of alzheimer's disease | |
AU2003251962A1 (en) | Screening for alzheimer's disease | |
AU2003299101A1 (en) | Compounds for the treatment of alzheimer's disease | |
AU2002242348A1 (en) | Process for obtaining 3'-epilutein | |
AU2002341044A1 (en) | Methods for detecting parkinson's disease | |
AU2001273675A1 (en) | Methods and assays for diagnosing alzheimer's disease | |
AU2001267826A1 (en) | Remedies for alzheimer's disease | |
AU2003230848A1 (en) | Methods and compositions for treating alzheimer's disease | |
AU2001258569A1 (en) | Alzheimer's disease assay | |
AU2001274413A1 (en) | Synthesis procedure for biphenylimidazolyl-(1)-phenylmethane and related compounds | |
AU2002364885A1 (en) | Alzheimer's disease model | |
AU2001255234A1 (en) | Cellular calcium responce for diagnosis of alzheimer's disease | |
AU2001255439A1 (en) | Method of treating alzheimer's disease |